RYOIX Rydex Biotechnology Inv Forecast, Technical & Fundamental Analysis

The most notable companies in this group are ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Moderna (NASDAQ:MRNA).

The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It may invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.

The average market capitalization across the Rydex Biotechnology Inv MF is 117.7B. The market cap for tickers in the group ranges from 9.78B to 375.5B. ABBV holds the highest valuation in this group at 375.5B. The lowest valued company is MRNA at 9.78B.

The average weekly volume growth across all stocks in the Rydex Biotechnology Inv MF was -8%. For the same stocks of the MF, the average monthly volume growth was -27% and the average quarterly volume growth was -51%